Auspex Pharmaceuticals (La Jolla, CA), a clinical-stage pharmaceutical company focused on hyperkinetic movement disorders including Huntington’s disease, Tourette syndrome and tardive dyskinesia, closed a $25M Series D financing. Participants include Panorama Capital, Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund.
Collective IP | The World’s Largest Technology Transfer Office Marketplace
Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets
Receive Collective IP Account Access HERE